In a report released today, Brandon Folkes from Cantor Fitzgerald maintained a Buy rating on Emergent Biosolutions (NYSE: EBS), with a price target of $68. The company’s shares opened today at $60.48, close to its 52-week high of $64.91.
“Emergent is the leader in the biodefense field and has carved out a high-barrier-to- entry niche in that market. As investors appreciate the durability and revenue potential of Emergent’s portfolio, we expect upward earnings revisions and multiple expansion to drive the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $68.”
According to TipRanks.com, Folkes is a 2-star analyst with an average return of 1.0% and a 44.4% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Opiant Pharmaceuticals Inc, and Eagle Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Emergent Biosolutions with a $63 average price target, representing a 4.2% upside. In a report issued on September 11, Argus Research also maintained a Buy rating on the stock with a $70 price target.
Emergent Biosolutions’ market cap is currently $3.02B and has a P/E ratio of 27.05. The company has a Price to Book ratio of 3.22.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures that address public health and national security threats. It includes Chemical, Biological, Radiological, Nuclear and Explosive or CBRNE threats; as well as emerging infectious diseases.